A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Orally Administered VG290131 in Healthy Adult Subjects
Latest Information Update: 29 Jul 2024
At a glance
- Drugs VG-290131 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Zhejiang Vimgreen Pharmaceuticals
Most Recent Events
- 26 Jul 2024 Planned End Date changed from 1 May 2024 to 1 Dec 2024.
- 26 Jul 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Dec 2024.
- 20 Oct 2023 New trial record